VenoVision

Company Overview

Snapshot

Founded in September 2022 by Nadav Lankin, Dr. Tal Hasin, Prof. Yaakov Nahmias, and Jonathan Maron, VenoVision operates with 1–10 employees. The company has raised $187.5K across five funding rounds. In November 2023, VenoVision secured a grant, indicating ongoing support for its innovative technology.

Business overview

VenoVision develops non-invasive advanced cardiac and hemodynamic monitoring solutions designed to improve care for millions of heart failure and at-risk patients. Its core technology is a low-cost, easy-to-use, thermal imaging-based hemodynamic monitoring device and platform. This technology brings ICU-level cardiac monitoring to lower resource settings, providing medical teams with critical data to adjust therapy, reduce ICU admissions, and prevent rehospitalizations. VenoVision serves the healthcare industry, focusing on inpatient, outpatient, and home care settings, and addresses the challenges of monitoring obese patients. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Devices.

Strategic signal

In March 2023, VenoVision was selected to participate in the MassChallenge HealthTech cohort. This selection signals significant industry validation for VenoVision's non-invasive cardiac monitoring technology, providing access to a founders-first curriculum, industry connections, and potential funding opportunities. For investors, this indicates strong growth potential and strategic alignment with key healthcare innovation ecosystems, positioning the company for accelerated development and market penetration.

Company Intelligence Q&A

What is VenoVision's core technology?

VenoVision's core technology is a patented, low-cost, easy-to-use, thermal imaging-based hemodynamic monitoring device and platform. This technology allows for non-invasive advanced cardiac monitoring, providing critical data for heart failure and at-risk patients.

When was VenoVision selected for the MassChallenge HealthTech cohort?

In March 2023, VenoVision was invited to participate in the MassChallenge HealthTech cohort, a program offering a founders-first curriculum, industry connections, and funding opportunities.

What was a significant early recognition for VenoVision?

In September 2022, VenoVision was selected for the Health Wildcatters 2022 Program, an accelerator focused on improving therapeutic management and patient outcomes through medical innovation.

When was a key patent granted to VenoVision?

On February 1, 2022, a patent (US20180184977A1) related to jugular venous assessment, originally filed by Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., was granted and assigned to VenoVision Inc.

What was VenoVision's involvement with MassChallenge Israel?

In March 2021, VenoVision was part of the MassChallenge Israel 2021 accelerator program cohort, which aims to prepare early-stage companies through mentorship, education, and connections.